<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DANTRIUM- dantrolene sodium capsule </strong><br>JHP Pharmaceuticals LLC<br></p></div>
<h1>Dantrium<span class="Sup">®</span> (dantrolene sodium) capsules</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Dantrium</span> (dantrolene sodium) has a potential for hepatotoxicity, and should not be used in conditions other than those recommended.  Symptomatic <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (fatal and non-fatal) has been reported at various dose levels of the drug.  The incidence reported in patients taking up to 400 mg/day is much lower than in those taking doses of 800 mg or more per day.  Even sporadic short courses of these higher dose levels within a treatment regimen markedly increased the risk of serious hepatic injury.  Liver dysfunction as evidenced by blood chemical abnormalities alone (liver enzyme elevations) has been observed in patients exposed to <span class="Bold">Dantrium</span> for varying periods of time.  Overt <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> has occurred at varying intervals after initiation of therapy, but has been most frequently observed between the third and twelfth month of therapy.  The risk of hepatic injury appears to be greater in females, in patients over 35 years of age, and in patients taking other medication(s) in addition to <span class="Bold">Dantrium</span> (dantrolene sodium). Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving Dantrium.  However, the majority of these cases were complicated with confounding factors such as intercurrent illnesses and/or concomitant potentially hepatotoxic medications (see <a href="#geriatric">Geriatric Use</a> subsection). <span class="Bold">Dantrium</span> should be used only in conjunction with appropriate monitoring of hepatic function including frequent determination of <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> or SGPT.  If no observable benefit is derived from the administration of <span class="Bold">Dantrium</span> after a total of 45 days, therapy should be discontinued.  The lowest possible effective dose for the individual patient should be prescribed.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">The chemical formula of <span class="Bold">Dantrium</span> (dantrolene sodium) is hydrated 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-2, 4-imidazolidinedione sodium salt.  It is an orange powder, slightly soluble in water, but due to its slightly acidic nature the solubility increases somewhat in alkaline solution.  The anhydrous salt has a molecular weight of 336.  The hydrated salt contains approximately 15% water (3-1/2 moles) and has a molecular weight of 399.  The structural formula for the hydrated salt is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57b4eec1-49e1-432c-95ae-0fe36e32d64b&amp;name=dantrium-01.jpg"></div>
<p><span class="Bold">Dantrium</span> is supplied in capsules of 25 mg, 50 mg, and 100 mg.</p>
<p><span class="Bold">Inactive Ingredients:</span>  Each capsule contains edible black ink, FD&amp;C Yellow No. 6, gelatin, lactose, magnesium stearate, starch, synthetic iron oxide red, synthetic iron oxide yellow, talc, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">In isolated nerve-muscle preparation, <span class="Bold">Dantrium</span> has been shown to produce relaxation by affecting the contractile response of the skeletal muscle at a site beyond the myoneural junction, directly on the muscle itself.  In skeletal muscle, <span class="Bold">Dantrium</span> dissociates the excitation-contraction coupling, probably by interfering with the release of Ca<span class="Sup">++</span> from the sarcoplasmic reticulum.  This effect appears to be more pronounced in fast muscle fibers as compared to slow ones, but generally affects both.  A central nervous system effect occurs, with <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> occasionally present.  Although <span class="Bold">Dantrium</span> does not appear to directly affect the CNS, the extent of its indirect effect is unknown.  The absorption of <span class="Bold">Dantrium</span> after oral administration in humans is incomplete and slow but consistent, and dose-related blood levels are obtained.  The duration and intensity of skeletal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> is related to the dosage and blood levels.  The mean biologic half-life of <span class="Bold">Dantrium</span> in adults is 8.7 hours after a 100-mg dose.  Specific metabolic pathways in the degradation and elimination of <span class="Bold">Dantrium</span> in human subjects have been established.  Metabolic patterns are similar in adults and pediatric patients.  In addition to the parent compound, dantrolene, which is found in measurable amounts in blood and urine, the major metabolites noted in body fluids are the 5-hydroxy analog and the acetamido analog.  Since <span class="Bold">Dantrium</span> is probably metabolized by hepatic microsomal enzymes, enhancement of its metabolism by other drugs is possible.  However, neither phenobarbital nor diazepam appears to affect <span class="Bold">Dantrium</span> metabolism.</p>
<p>Clinical experience in the management of fulminant human <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>, as well as experiments conducted in <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> susceptible swine, have revealed that the administration of intravenous dantrolene, combined with indicated supportive measures, is effective in reversing the hypermetabolic process of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>.  Known differences between human and swine <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> are minor.  The <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> administration of oral or intravenous dantrolene to <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> susceptible swine will attenuate or prevent the development of signs of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> in a manner dependent upon the dosage of dantrolene administered and the intensity of the <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> triggering stimulus.  Limited clinical experience with the administration of oral dantrolene to patients judged <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> susceptible, when combined with clinical experience in the use of intravenous dantrolene for the treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> and data derived from the above cited animal model experiments, suggests that oral dantrolene will also attenuate or prevent the development of signs of human <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>, provided that currently accepted practices in the management of such patients are adhered to (see <span class="Bold"><a href="#usage">INDICATIONS AND USAGE</a></span>); intravenous dantrolene should also be available for use should the signs of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> appear.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="usage"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>In Chronic <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">Spasticity</span></h2>
<p class="First"><span class="Bold">Dantrium</span> is indicated in controlling the manifestations of clinical <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> resulting from upper motor neuron disorders (e.g., <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">spinal cord injury</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4134120" conceptname="Cerebral palsy">cerebral palsy</span>, or <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>).  It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span>.  Such patients must have presumably reversible <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> where relief of <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> will aid in restoring residual function.  <span class="Bold">Dantrium</span> is not indicated in the treatment of skeletal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> resulting from rheumatic disorders.</p>
<p>If improvement occurs, it will ordinarily occur within the dosage titration (see <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>), and will be manifested by a decrease in the severity of <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> and the ability to resume a daily function not quite attainable without <span class="Bold">Dantrium.</span></p>
<p>Occasionally, subtle but meaningful improvement in <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> may occur with <span class="Bold">Dantrium</span> therapy.  In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him.  Brief withdrawal of <span class="Bold">Dantrium</span> for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> and may serve to confirm a clinical impression.</p>
<p>A decision to continue the administration of <span class="Bold">Dantrium</span> on a long-term basis is justified if introduction of the drug into the patient's regimen:</p>
<dl>
<dt> </dt>
<dd>produces a significant reduction in painful and/or disabling <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> such 	as <span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonus</span>, or</dd>
<dt> </dt>
<dd>  </dd>
<dt> </dt>
<dd>permits a significant reduction in the intensity and/or degree of nursing care required, or</dd>
<dt> </dt>
<dd>  </dd>
<dt> </dt>
<dd>rids the patient of any annoying manifestation of <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> considered 	important by the patient himself.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>In <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span></h2>
<p class="First">Oral <span class="Bold">Dantrium</span> is also indicated preoperatively to prevent or attenuate the development of signs of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> in known, or strongly suspect, <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> susceptible patients who require anesthesia and/or surgery.  Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>, minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> appear); see also the package insert for <span class="Bold">Dantrium</span><span class="Sup">®</span> (dantrolene sodium) <span class="Bold">Intravenous.</span></p>
<p>Oral <span class="Bold">Dantrium</span> should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Active <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and cirrhosis, is a contraindication for use of <span class="Bold">Dantrium</span>.  <span class="Bold">Dantrium</span> is contraindicated where <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> is utilized to sustain upright posture and balance in locomotion or whenever <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> is utilized to obtain or maintain increased function.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warn"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">It is important to recognize that fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorders</span> of an idiosyncratic or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> type may occur with <span class="Bold">Dantrium</span> therapy.</p>
<p>At the start of <span class="Bold">Dantrium</span> therapy, it is desirable to do liver function studies (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, alkaline phosphatase, total bilirubin) for a baseline or to establish whether there is pre-existing liver disease.  If baseline liver abnormalities exist and are confirmed, there is a clear possibility that the potential for <span class="Bold">Dantrium</span> hepatotoxicity could be enhanced, although such a possibility has not yet been established.</p>
<p>Liver function studies (e.g., <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> or SGPT) should be performed at appropriate intervals during <span class="Bold">Dantrium</span> therapy.  If such studies reveal abnormal values, therapy should generally be discontinued.  Only where benefits of the drug have been of major importance to the patient, should reinitiation or continuation of therapy be considered.  Some patients have revealed a return to normal laboratory values in the face of continued therapy while others have not.</p>
<p>If symptoms compatible with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, accompanied by abnormalities in liver function tests or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> appear, <span class="Bold">Dantrium</span> should be discontinued.  If caused by <span class="Bold">Dantrium</span> and detected early, the abnormalities in liver function characteristically have reverted to normal when the drug was discontinued.  </p>
<p><span class="Bold">Dantrium</span> therapy has been reinstituted in a few patients who have developed clinical and/or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular injury</span>.  If such reinstitution of therapy is done, it should be attempted only in patients who clearly need <span class="Bold">Dantrium</span> and only after previous symptoms and laboratory abnormalities have cleared.  The patient should be hospitalized and the drug should be restarted in very small and gradually increasing doses.  Laboratory monitoring should be frequent and the drug should be withdrawn immediately if there is any indication of recurrent liver involvement.  Some patients have reacted with unmistakable signs of liver abnormality upon administration of a challenge dose, while others have not.</p>
<p><span class="Bold">Dantrium</span> should be used with particular caution in females and in patients over 35 years of age in view of apparent greater likelihood of drug-induced, potentially fatal, hepatocellular disease in these groups. Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving <span class="Bold">Dantrium.</span>  However, the majority of these cases were complicated with confounding factors such as intercurrent illnesses and/or concomitant potentially hepatotoxic medications (see <a href="#geriatric">Geriatric Use</a> subsection).</p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-5.1"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term safety of <span class="Bold">Dantrium</span> in humans has not been established.  Chronic studies in rats, dogs, and monkeys at dosages greater than 30 mg/kg/day showed growth or weight <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and signs of hepatopathy and possible occlusion <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span>, all of which were reversible upon cessation of treatment. Sprague-Dawley female rats fed dantrolene sodium for 18 months at dosage levels of 15, 30, and 60 mg/kg/day showed an increased incidence of benign and malignant mammary tumors compared with concurrent controls.  At the highest dose level, there was an increase in the incidence of benign lymphatic neoplasms.  In a 30-month study at the same dose levels also in Sprague-Dawley rats, dantrolene sodium produced a decrease in the time of onset of mammary neoplasms.  Female rats at the highest dose level showed an increased incidence of hepatic lymphangiomas and hepatic angiosarcomas.</p>
<p>The only drug-related effect seen in a 30-month study in Fischer-344 rats was a dose-related reduction in the time of onset of mammary and testicular tumors.  A 24-month study in HaM/ICR mice revealed no evidence of carcinogenic activity.  Carcinogenicity in humans cannot be fully excluded, so that this possible risk of chronic administration must be weighed against the benefits of the drug (i.e., after a brief trial) for the individual patient.</p>
<p>Dantrolene sodium has produced positive results in the Ames S. Typhimurium bacterial mutagenesis assay in the presence and absence of a liver activating system.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-5.2"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-5.2.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Adequate animal reproduction studies have not been conducted with Dantrium.  It is also not known whether Dantrium can cause fatal harm when administered to a pregnant woman or can affect reproduction capacity.  Dantrium should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="lab"></a><a name="section-5.3"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">In one non-randomized open-label study, 21 term pregnant patients received <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> oral <span class="Bold">Dantrium</span> 100 mg per day for 2 to 10 days prior to delivery.  Dantrolene readily crossed the placenta with maternal and fetal whole blood levels approximately equal at delivery; neonatal levels then fell approximately 50% per day for 2 days before declining sharply.  No neonatal respiratory and neuromuscular side effects were detected at low dose. More data, at higher doses, are needed before more definitive conclusions can be made.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-5.4"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><span class="Bold">Dantrium</span> should not be used in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-5.5"></a><p></p>
<h2>Usage in Pediatric Patients</h2>
<p class="First">The long-term safety of <span class="Bold">Dantrium</span> in pediatric patients under the age of 5 years has not been established.  Because of the possibility that adverse effects of the drug could become apparent only after many years, a benefit-risk consideration of the long-term use of <span class="Bold">Dantrium</span> is particularly important in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="geriatric"></a><a name="section-5.6"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of <span class="Bold">Dantrium</span> did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience in the literature has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.  As with all patients receiving <span class="Bold">Dantrium</span>, it is recommended that elderly patients receive the lowest dose compatible with the optimal response.  Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving <span class="Bold">Dantrium</span>.  However, the majority of these cases were complicated with confounding factors such as intercurrent illnesses and/or concomitant potentially hepatotoxic medications (for hepatotoxicity details and its management see <a href="#BOX">Black Box</a> and <a href="#warn">Warnings</a> Sections).
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-5.7"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> may occur with <span class="Bold">Dantrium</span> therapy, and the concomitant administration of CNS depressants such as sedatives and tranquilizing agents may result in further <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>.</p>
<p>While a definite drug interaction with estrogen therapy has not yet been established, caution should be observed if the two drugs are to be given concomitantly.  Hepatotoxicity has occurred more often in women over 35 years of age receiving concomitant estrogen therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Cardiovascular collapse</span> in patients treated simultaneously with verapamil and dantrolene sodium is rare.  The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane/α-chloralose anesthetized swine has resulted in <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> in association with marked <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.  Until the relevance of these findings to humans is established, the combination of dantrolene sodium and calcium channel blockers is not recommended during the management of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>.</p>
<p>Administration of <span class="Bold">Dantrium</span> may potentiate vecuronium-induced neuromuscular block.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold">Dantrium</span> should be used with caution in patients with impaired pulmonary function, particularly those with obstructive pulmonary disease, and in patients with severely impaired cardiac function due to myocardial disease. Dantrium is associated with <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> with associated <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. It should be used with caution in patients with a history of previous liver disease or dysfunction (see <span class="Bold"><a href="#warn">WARNINGS</a></span>).</p>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.1"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be cautioned against driving a motor vehicle or participating in hazardous occupations while taking <span class="Bold">Dantrium</span>.  Caution should be exercised in the concomitant administration of tranquilizing agents.</p>
<p><span class="Bold">Dantrium</span> might possibly evoke a <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>; patients should be cautioned about exposure to sunlight while taking it.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequently occurring side effects of <span class="Bold">Dantrium</span> have been <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  These are generally transient, occurring early in treatment, and can often be obviated by beginning with a low dose and increasing dosage gradually until an optimal regimen is established.  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may be severe and may necessitate temporary withdrawal of <span class="Bold">Dantrium</span> therapy.  If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> recurs upon readministration of <span class="Bold">Dantrium</span>, therapy should probably be withdrawn permanently.</p>
<p>Other less frequent side effects, listed according to system, are:</p>
<p><span class="Bold">Gastrointestinal:</span>  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, rarely progressing to signs of <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold">Hepatobiliary:</span>  <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> (see <span class="Bold"><a href="#warn">WARNINGS</a></span>).</p>
<p><span class="Bold">Neurologic:</span>  Speech disturbance, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, light-headedness, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, alteration of taste, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>.</p>
<p><span class="Bold">Cardiovascular:</span>  <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, erratic blood pressure, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<p><span class="Bold">Hematologic:</span>  <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">lymphocytic lymphoma</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold">Psychiatric:</span>  Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, increased <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>.</p>
<p><span class="Bold">Urogenital:</span>  <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Increased urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, difficult erection, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span> and/or <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, difficult urination and/or <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
<p><span class="Bold">Integumentary:</span>  <span class="product-label-link" type="condition" conceptid="4309771" conceptname="Abnormal hair growth">Abnormal hair growth</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>-like <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, eczematoid <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
<p><span class="Bold">Musculoskeletal:</span>  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>.</p>
<p><span class="Bold">Respiratory:</span>  Feeling of <span class="product-label-link" type="condition" conceptid="4139960" conceptname="Strangulation">suffocation</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p><span class="Bold">Special Senses:</span>  Excessive tearing.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span>  <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span> with <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> with associated <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p><span class="Bold">Other:</span>  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
<p>The published literature has included some reports of <span class="Bold">Dantrium</span> use in patients with <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS).  <span class="Bold">Dantrium</span> capsules are not indicated for the treatment of NMS and patients may expire despite treatment with <span class="Bold">Dantrium</span> capsules.</p>
<p>For medical advice about adverse reactions contact your medical professional.  To report SUSPECTED ADVERSE REACTIONS, contact JHP at 1-866-923-2547 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.fda.gov/medwatch/.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Drug abuse and dependency potential has not been evaluated in human or animal studies.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Symptoms which may occur in case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include, but are not limited to, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> and alterations in the state of consciousness (e.g. <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>.  For <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>, general supportive measures should be employed along with immediate gastric lavage.</p>
<p>Intravenous fluids should be administered in fairly large quantities to avert the possibility of <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>.  An adequate airway should be maintained and artificial resuscitation equipment should be at hand.  Electrocardiographic monitoring should be instituted, and the patient carefully observed.  To date, no experience has been reported with dialysis and its value in Dantrium <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is not known.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>For Use in Chronic <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">Spasticity</span></h2>
<p class="First">Prior to the administration of <span class="Bold">Dantrium</span>, consideration should be given to the potential response to treatment.  A decrease in <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> sufficient to allow a daily function not otherwise attainable should be the therapeutic goal of treatment with <span class="Bold">Dantrium</span>.  Refer to <span class="Bold"><a href="#usage">INDICATIONS AND USAGE</a></span> section for description of response to be anticipated.</p>
<p>It is important to establish a therapeutic goal (regain and maintain a specific function such as therapeutic exercise program, utilization of braces, transfer maneuvers, etc.) before beginning <span class="Bold">Dantrium</span> therapy.  Dosage should be increased until the maximum performance compatible with the dysfunction due to underlying disease is achieved.  No further increase in dosage is then indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Usual Dosage</h2>
<p class="First">It is important that the dosage be titrated and individualized for maximum effect.  The lowest dose compatible with optimal response is recommended.</p>
<p><span class="Italics">In view of the potential for <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> in long-term</span><span class="Bold"> Dantrium </span><span class="Italics">use, therapy should be stopped if benefits are not evident within 45 days.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Adults</h2>
<p class="First">The following gradual titration schedule is suggested.  Some patients will not respond until higher daily dosage is achieved.  Each dosage level should be maintained for seven days to determine the patient's response.  If no further benefit is observed at the next higher dose, dosage should be decreased to the previous lower dose.</p>
<dl>
<dt> </dt>
<dd>25 mg once daily for seven days, then</dd>
<dt> </dt>
<dd>25 mg t.i.d. for seven days</dd>
<dt> </dt>
<dd>50 mg t.i.d. for seven days</dd>
<dt> </dt>
<dd>100 mg t.i.d.</dd>
</dl>
<p>Therapy with a dose four times daily may be necessary for some individuals.  Doses higher than 100 mg four times daily should not be used.  (See <a href="#BOX">Box Warning</a>.)</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-10.4"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">The following gradual titration schedule is suggested.  Some patients will not respond until higher daily dosage is achieved.  Each dosage level should be maintained for seven days to determine the patient's response.  If no further benefit is observed at the next higher dose, dosage should be decreased to the previous lower dose.</p>
<dl>
<dt> </dt>
<dd>0.5 mg/kg once daily for seven days, then</dd>
<dt> </dt>
<dd>0.5 mg/kg t.i.d. for seven days</dd>
<dt> </dt>
<dd>1 mg/kg t.i.d. for seven days</dd>
<dt> </dt>
<dd>2 mg/kg t.i.d.</dd>
</dl>
<p>Therapy with a dose four times daily may be necessary for some individuals.  Doses higher than 100 mg four times daily should not be used.  (See <a href="#BOX">Box Warning</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5"></a><p></p>
<h2>For <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.1"></a><p></p>
<p class="First"><span class="Bold">Preoperatively</span></p>
<p>Administer 4 to 8 mg/kg/day of oral <span class="Bold">Dantrium</span> in 3 or 4 divided doses for one or two days prior to surgery, with the last dose being given approximately 3 to 4 hours before scheduled surgery with a minimum of water.</p>
<p>This dosage will usually be associated with skeletal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and sedation (<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>); adjustment can usually be made within the recommended dosage range to avoid incapacitation or excessive <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span> (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.2"></a><p></p>
<p class="First"><span class="Bold">Post Crisis Follow-up</span></p>
<p>Oral <span class="Bold">Dantrium</span> should also be administered following a <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> crisis, in doses of 4 to 8 mg/kg per day in four divided doses, for a one to three day period to prevent recurrence of the manifestations of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Dantrium</span>  (dantrolene sodium) is available in:</p>
<table width="100%">
<col align="left" valign="bottom" width="25%">
<col align="left" valign="bottom" width="75%">
<tbody class="Headless">
<tr class="First TopRule"><td align="left" colspan="2">25-mg opaque, orange and tan capsules imprinted with DANTRIUM 25 mg on the cap and 0149 0030 with a single bar on the body.</td></tr>
<tr>
<td align="left">
<span class="Bold">NDC</span>  42023-124-01</td>
<td align="left">bottle of 100</td>
</tr>
<tr><td align="left" colspan="2">50-mg opaque, orange and tan capsules imprinted with DANTRIUM 50 mg on the cap and 0149 0031 with a double bar on the body.</td></tr>
<tr>
<td align="left">
<span class="Bold">NDC</span>  42023-125-01</td>
<td align="left">bottle of 100</td>
</tr>
<tr><td align="left" colspan="2">100-mg opaque, orange and tan capsules imprinted with DANTRIUM 100 mg on the cap and 0149 0033 with a triple bar on the body.</td></tr>
<tr class="BotRule Last">
<td align="left">
<span class="Bold">NDC</span>  42023-126-01</td>
<td align="left">bottle of 100</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Store between 20° to 25°C (68° to 77°F).  (See USP Controlled Room Temperature.)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Rx Only.</p>
<p>Prescribing information as of July 2012.</p>
<p>Distributed by:<br>  JHP Pharmaceuticals, LLC.<br>Rochester, MI, 48307</p>
<p>3003041C</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 25 mg Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 42023-124-01</p>
<p><span class="Bold">25 mg</span></p>
<p><span class="Bold">Dantrium<span class="Sup">®</span></span><br>(dantrolene sodium)</p>
<p><span class="Bold">PERIPHERAL SKELETAL<br>MUSCLE RELAXANT</span></p>
<p><span class="Bold">100 Capsules</span><br>Rx Only</p>
<p><span class="Bold">JHP<br>PHARMACEUTICALS</span></p>
<div class="Figure"><img alt="Principle Display Panel - 25 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57b4eec1-49e1-432c-95ae-0fe36e32d64b&amp;name=dantrium-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mg Bottle label</h1>
<p class="First"><span class="Bold">NDC</span> 42023-125-01</p>
<p><span class="Bold">50 mg</span></p>
<p><span class="Bold">Dantrium<span class="Sup">®</span></span><br>(dantrolene sodium)</p>
<p><span class="Bold">PERIPHERAL SKELETAL<br>MUSCLE RELAXANT</span></p>
<p><span class="Bold">100 Capsules</span><br>Rx Only</p>
<p><span class="Bold">JHP<br>PHARMACEUTICALS</span></p>
<div class="Figure"><img alt="Principle Display Panel - 50 mg Bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57b4eec1-49e1-432c-95ae-0fe36e32d64b&amp;name=dantrium-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 42023-126-01</p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold">Dantrium<span class="Sup">®</span></span><br>(dantrolene sodium)</p>
<p><span class="Bold">PERIPHERAL SKELETAL<br>MUSCLE RELAXANT</span></p>
<p><span class="Bold">100 Capsules</span></p>
<p>Rx Only</p>
<p><span class="Bold">JHP<br>PHARMACEUTICALS</span></p>
<div class="Figure"><img alt="Principle Display Panel - 100 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57b4eec1-49e1-432c-95ae-0fe36e32d64b&amp;name=dantrium-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DANTRIUM 		
					</strong><br><span class="contentTableReg">dantrolene sodium capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42023-124</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dantrolene sodium</strong> (dantrolene) </td>
<td class="formItem">dantrolene</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Magnesium Stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Titanium Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE, BROWN (tan) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Dantrium;25mg;0149;0030</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42023-124-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017443</td>
<td class="formItem">08/01/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DANTRIUM 		
					</strong><br><span class="contentTableReg">dantrolene sodium capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42023-125</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dantrolene sodium</strong> (dantrolene) </td>
<td class="formItem">dantrolene</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Magnesium Stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Titanium Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE, BROWN (tan) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Dantrium;50mg;0149;0031</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42023-125-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017443</td>
<td class="formItem">08/01/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DANTRIUM 		
					</strong><br><span class="contentTableReg">dantrolene sodium capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42023-126</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dantrolene sodium</strong> (dantrolene) </td>
<td class="formItem">dantrolene</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Magnesium Stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Titanium Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE, BROWN (tan) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Dantrium;100mg;0149;0033</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42023-126-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017443</td>
<td class="formItem">08/01/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>JHP Pharmaceuticals LLC
							(804894611)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ddfaaf61-fe76-44f3-9893-a6c04ecacbce</div>
<div>Set id: 57b4eec1-49e1-432c-95ae-0fe36e32d64b</div>
<div>Version: 6</div>
<div>Effective Time: 20120725</div>
</div>
</div> <div class="DistributorName">JHP Pharmaceuticals LLC</div></p>
</body></html>
